ALNYLAM PHARMACEUTICALS, INC. Quarterly Income Tax Expense (Benefit) in USD from Q1 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Alnylam Pharmaceuticals, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q1 2010 to Q3 2024.
  • Alnylam Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $2.91M, a 2.71% decline year-over-year.
  • Alnylam Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was $11.2M, a 59.1% increase year-over-year.
  • Alnylam Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2023 was $6.73M, a 61.5% increase from 2022.
  • Alnylam Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2022 was $4.16M, a 512% increase from 2021.
  • Alnylam Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2021 was $680K, a 74.6% decline from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $11.2M $2.91M -$81K -2.71% Jul 1, 2024 Sep 30, 2024 10-Q 2024-10-31
Q2 2024 $11.2M $5.72M +$3.91M +215% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-01
Q1 2024 $7.33M $2.35M +$609K +35% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-02
Q4 2023 $6.73M $183K -$289K -61.2% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-15
Q3 2023 $7.01M $2.99M +$3.01M Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-31
Q2 2023 $4M $1.82M -$914K -33.5% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 $4.92M $1.74M +$754K +76.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q4 2022 $4.16M $472K +$2.31M Oct 1, 2022 Dec 31, 2022 10-K 2024-02-15
Q3 2022 $1.85M -$23K -$301K -108% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $2.15M $2.73M +$1.5M +122% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 $649K $985K -$31K -3.05% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $680K -$1.84M -$1.78M -3022% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-15
Q3 2021 $2.46M $278K -$561K -66.9% Jul 1, 2021 Sep 30, 2021 10-Q 2022-10-27
Q2 2021 $3.02M $1.23M -$98K -7.39% Apr 1, 2021 Jun 30, 2021 10-Q 2022-07-28
Q1 2021 $3.12M $1.02M +$441K +76.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-04-28
Q4 2020 $2.68M -$59K +$339K +85.2% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-23
Q3 2020 $2.34M $839K +$1.23M Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-28
Q2 2020 $1.11M $1.33M +$366K +38.1% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-03
Q1 2020 $743K $575K -$120K -17.3% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-29
Q4 2019 $863K -$398K -$759K -210% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-10
Q3 2019 $1.62M -$394K -$839K -189% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $2.46M $960K +$881K +1115% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $1.58M $695K +$757K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-06
Q4 2018 $823K $361K Oct 1, 2018 Dec 31, 2018 10-K 2021-02-11
Q3 2018 $445K Jul 1, 2018 Sep 30, 2018 10-Q 2019-10-31
Q2 2018 $79K Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
Q1 2018 -$62K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-02
Q4 2013 -$2.7M $3.02M Oct 1, 2013 Dec 31, 2013 10-K 2016-02-12
Q3 2013 -$2.27M Jul 1, 2013 Sep 30, 2013 10-Q 2013-11-07
Q2 2013 -$2.88M Apr 1, 2013 Jun 30, 2013 10-Q 2013-08-09
Q1 2013 -$562K Jan 1, 2013 Mar 31, 2013 10-Q 2013-05-07
Q4 2010 $514K $427K Oct 1, 2010 Dec 31, 2010 10-K 2013-02-19
Q3 2010 $298K Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-03
Q2 2010 -$229K Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-03
Q1 2010 $18K Jan 1, 2010 Mar 31, 2010 10-Q 2011-05-05
* An asterisk sign (*) next to the value indicates that the value is likely invalid.